阿帕替尼治疗晚期胃癌的临床疗效及不良反应分析

Analysis of the clinical efficacy and adverse reactions of apatinib in the treatment of advanced gastric cancer

目的探究阿帕替尼治疗晚期胃癌的临床效果以及不良反应发生情况。方法 102例晚期胃癌患者,随机分为研究组和参照组,每组51例。参照组采取基础治疗方案,研究组在基础治疗上予以阿帕替尼治疗。比较两组患者治疗效果、治疗前后相关指标[癌胚抗原(CEA)、糖链抗原(CA)19-9、CA72-4]以及不良反应发生情况。结果研究组治疗总有效率96.1%显著高于参照组的80.4%,差异具有统计学意义有(P<0.05)。治疗后,研究组患者CEA、CA19-9、CA72-4水平分别为(27.1±2.1)ng/L、(96.4±1.7)U/ml、(47.3±2.2)U/ml,均低于参照组的(31.4±2.9)ng/L、(111.3±1.9)U/ml、(54.6±2.5)U/ml,差异均具有统计学意义(P<0.05)。研究组不良反应发生率11.8%显著低于参照组的29.4%,差异具有统计学意义(P<0.05)。结论阿帕替尼治疗晚期胃癌的临床效果较好,显著优于传统治疗方式,有效提升了晚期胃癌患者的生存质量,缓解了患者的经济压力,提升了患者及家庭的生活质量,适用于临床推广应用。

Objective To investigate the clinical effect and occurrence of adverse reactions of apatinib in the treatment of advanced gastric cancer. Methods A total of 102 patients with advanced gastric cancer were randomly divided into research group and reference group, with 51 cases in each group. The reference group was treated with basic therapy, and the research group was treated with apatinib based on basic therapy. The therapeutic effect, related indicators [carcinoembryonic antigen(CEA), carbohydrate antigen(CA) 19-9, CA72-4] before and after treatment, and occurrence of adverse reactions were compared between the two groups. Results The total effective rate 96.1% of the research group was significantly higher than 80.4% of the reference group, and the difference was statistically significant(P<0.05). After treatment, the levels of CEA, CA19-9 and CA72-4 of the research group were(27.1±2.1) ng/L,(96.4±1.7) U/ml and(47.3±2.2) U/ml, which were all lower than(31.4±2.9)ng/L,(111.3±1.9) U/ml and(54.6±2.5) U/ml of the reference group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions 11.8% of the research group was significantly lower than 29.4% of the reference group, and the difference was statistically significant(P<0.05). Conclusion Apatinib shows significantly better clinical effect in the treatment of advanced gastric cancer, which can effectively improve the quality of life of patients, relieve their economic pressure, and improve the quality of life of patients and families, which is suitable for clinical promotion and application.